Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion.

Hellinger JW, Hüchel S, Goetz L, Bauerschmitz G, Emons G, Gründker C.

Front Oncol. 2019 Oct 23;9:1074. doi: 10.3389/fonc.2019.01074. eCollection 2019.

2.

Adjuvant treatment for endometrial cancer.

Emons G, Vordermark D.

Curr Opin Oncol. 2019 Sep;31(5):404-410. doi: 10.1097/CCO.0000000000000558.

PMID:
31233482
3.

Induced Chromosomal Aneuploidy Results in Global and Consistent Deregulation of the Transcriptome of Cancer Cells.

Wangsa D, Braun R, Stuelten CH, Brown M, Bauer KM, Emons G, Weston LA, Hu Y, Yang HH, Vila-Casadesús M, Lee MP, Brauer P, Warner L, Upender M, Hummon AB, Camps J, Ried T.

Neoplasia. 2019 Jul;21(7):721-729. doi: 10.1016/j.neo.2019.04.009. Epub 2019 Jun 4.

4.

Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.

Gründker C, Wokoun U, Hellriegel M, Emons G.

J Obstet Gynaecol Res. 2019 Jul;45(7):1334-1342. doi: 10.1111/jog.13980. Epub 2019 Apr 23.

PMID:
31016845
5.

Mechanisms of Metastasis and Cell Mobility - The Role of Metabolism.

Gründker C, Läsche M, Hellinger JW, Emons G.

Geburtshilfe Frauenheilkd. 2019 Feb;79(2):184-188. doi: 10.1055/a-0805-9113. Epub 2019 Feb 18.

6.

[S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium : Requirements for pathology].

Horn LC, Emons G, Aretz S, Bock N, Follmann M, Lax S, Nothacker M, Steiner E, Mayr D; Deutsche Krebsgesellschaft (DKG); Kommission zur Erstellung der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“.

Pathologe. 2019 Feb;40(1):21-35. doi: 10.1007/s00292-019-0574-7. Review. German.

PMID:
30756154
7.

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER.

Girgert R, Emons G, Gründker C.

Front Endocrinol (Lausanne). 2019 Jan 9;9:781. doi: 10.3389/fendo.2018.00781. eCollection 2018. Review.

8.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities.

Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Lax S, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1089-1109. doi: 10.1055/a-0715-2964. Epub 2018 Nov 26.

9.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648
10.

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study.

Emons G, Tempfer C, Battista MJ, Mustea A, Vordermark D.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):923-926. doi: 10.1055/a-0658-1918. Epub 2018 Oct 19.

11.

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Sigurd L, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):949-971. doi: 10.1055/a-0713-1218. Epub 2018 Oct 19.

12.

Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.

Girgert R, Emons G, Gründker C.

Oncol Lett. 2018 Jun;15(6):9559-9566. doi: 10.3892/ol.2018.8521. Epub 2018 Apr 18.

13.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.

14.

Colorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery.

Hu Y, Gaedcke J, Emons G, Beissbarth T, Grade M, Jo P, Yeager M, Chanock SJ, Wolff H, Camps J, Ghadimi BM, Ried T.

Genes Chromosomes Cancer. 2018 Mar;57(3):140-149. doi: 10.1002/gcc.22512. Epub 2017 Nov 28.

15.

Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.

van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A; eusomaDB Working Group.

Eur J Cancer. 2017 Nov;85:15-22. doi: 10.1016/j.ejca.2017.07.040. Epub 2017 Sep 4.

PMID:
28881247
16.

The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis.

Gründker C, Emons G.

Front Endocrinol (Lausanne). 2017 Aug 4;8:187. doi: 10.3389/fendo.2017.00187. eCollection 2017. Review.

17.

Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling.

Emons G, Spitzner M, Reineke S, Möller J, Auslander N, Kramer F, Hu Y, Beissbarth T, Wolff HA, Rave-Fränk M, Heßmann E, Gaedcke J, Ghadimi BM, Johnsen SA, Ried T, Grade M.

Mol Cancer Res. 2017 Nov;15(11):1481-1490. doi: 10.1158/1541-7786.MCR-17-0205. Epub 2017 Aug 15.

18.

Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.

Wokoun U, Hellriegel M, Emons G, Gründker C.

Oncol Rep. 2017 Apr;37(4):2418-2424. doi: 10.3892/or.2017.5491. Epub 2017 Mar 6.

PMID:
28350075
19.

17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.

Girgert R, Emons G, Gründker C.

Oncol Rep. 2017 Feb;37(2):1212-1218. doi: 10.3892/or.2016.5306. Epub 2016 Dec 8.

PMID:
27959426
20.

Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH.

Gründker C, Bauerschmitz G, Schubert A, Emons G.

Int J Oncol. 2016 Jun;48(6):2713-21. doi: 10.3892/ijo.2016.3491. Epub 2016 Apr 18.

PMID:
27098123
21.

Erratum to: Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.

Ziegler E, Hansen MT, Haase M, Emons G, Gründker C.

Breast Cancer Res Treat. 2016 Feb;156(1):209-10. doi: 10.1007/s10549-016-3733-z. No abstract available.

PMID:
26931449
22.

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.

Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

J Med Genet. 2016 Jul;53(7):465-71. doi: 10.1136/jmedgenet-2015-103672. Epub 2016 Feb 29.

PMID:
26928436
23.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.

Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28.

PMID:
26731724
24.

The effect of EUSOMA certification on quality of breast cancer care.

van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, Kimmig R, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group:; eusomaDB Working Group.

Eur J Surg Oncol. 2015 Oct;41(10):1423-9. doi: 10.1016/j.ejso.2015.06.006. Epub 2015 Jun 24.

PMID:
26278019
25.

Inhibition of SDF-1/CXCR4-induced epithelial-mesenchymal transition by kisspeptin-10.

Gründker C, Bauerschmitz G, Knapp J, Schmidt E, Olbrich T, Emons G.

Breast Cancer Res Treat. 2015 Jul;152(1):41-50. doi: 10.1007/s10549-015-3463-7. Epub 2015 Jun 11.

PMID:
26062751
26.

New WHO Classification of Endometrial Hyperplasias.

Emons G, Beckmann MW, Schmidt D, Mallmann P; Uterus commission of the Gynecological Oncology Working Group (AGO).

Geburtshilfe Frauenheilkd. 2015 Feb;75(2):135-136. No abstract available.

27.

Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.

Girgert R, Emons G, Gründker C.

BMC Cancer. 2014 Dec 11;14:935. doi: 10.1186/1471-2407-14-935.

28.

Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.

Hinsche O, Girgert R, Emons G, Gründker C.

Int J Oncol. 2015 Feb;46(2):878-84. doi: 10.3892/ijo.2014.2778. Epub 2014 Nov 25.

PMID:
25420519
29.

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors.

Ray-Coquard I, Brown J, Harter P, Provencher DM, Fong PC, Maenpaa J, Ledermann JA, Emons G, Rigaud DB, Glasspool RM, Mezzanzanica D, Colombo N.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7. doi: 10.1097/IGC.0000000000000249. Review.

PMID:
25341579
30.

Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.

Ziegler E, Hansen MT, Haase M, Emons G, Gründker C.

Breast Cancer Res Treat. 2014 Nov;148(2):269-77. doi: 10.1007/s10549-014-3159-4. Epub 2014 Oct 8. Erratum in: Breast Cancer Res Treat. 2016 Feb;156(1):209-10.

PMID:
25292421
31.

Significance of lymph node dissection in gynecological oncology.

Emons G.

Oncol Res Treat. 2014;37(9):500-4. doi: 10.1159/000366248. Epub 2014 Aug 11. Review.

32.

Fulminant Puerperal Sepsis caused by Hemolytic Group A Streptococci and Toxic Shock Syndrome - A Case Report and Review of the Literature.

Bauerschmitz GJ, Hellriegel M, Strauchmann J, Schäper J, Emons G.

Geburtshilfe Frauenheilkd. 2014 Aug;74(8):764-767. No abstract available.

33.

Innovations in Cervical and Endometrial Cancer.

Mallmann P, Beckmann MW, Emons G.

Geburtshilfe Frauenheilkd. 2013 Sep;73(9):908-910.

34.

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C.

Geburtshilfe Frauenheilkd. 2013 Sep;73(9):874-889. No abstract available.

35.

Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).

Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P.

Gynecol Oncol. 2014 Jun;133(3):427-32. doi: 10.1016/j.ygyno.2014.03.576. Epub 2014 Apr 5.

PMID:
24713545
36.

Recommendations for the Diagnosis and Treatment of Endometrial Cancer, Update 2013.

Emons G, Mallmann P; acting for the Uterus Commission of AGO.

Geburtshilfe Frauenheilkd. 2014 Mar;74(3):244-247. No abstract available.

37.

Response of the Uterus Commission of AGO to the Comment of M. Kolben, C. Dannecker and R. Kürzl.

Emons G, Mallmann P; acting for the Uterus Commission of AGO.

Geburtshilfe Frauenheilkd. 2014 Mar;74(3):250. No abstract available.

38.

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

Emons G, Gorchev G, Harter P, Wimberger P, Stähle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J.

Int J Gynecol Cancer. 2014 Feb;24(2):260-5. doi: 10.1097/IGC.0000000000000044.

39.

Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells.

Schmidt E, Haase M, Ziegler E, Emons G, Gründker C.

Int J Gynecol Cancer. 2014 Feb;24(2):210-7. doi: 10.1097/IGC.0000000000000050.

PMID:
24407584
40.

STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.

Spitzner M, Roesler B, Bielfeld C, Emons G, Gaedcke J, Wolff HA, Rave-Fränk M, Kramer F, Beissbarth T, Kitz J, Wienands J, Ghadimi BM, Ebner R, Ried T, Grade M.

Int J Cancer. 2014 Feb 15;134(4):997-1007. doi: 10.1002/ijc.28429. Epub 2013 Sep 3.

41.

[General principles of tumour biology in visceral surgery].

Emons G, Ghadimi M, Grade M.

Zentralbl Chir. 2015 Feb;140(1):74-82. doi: 10.1055/s-0032-1328590. Epub 2013 Aug 5. Review. German.

PMID:
23918723
42.

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).

You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.

Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013. Epub 2013 May 18.

PMID:
23694718
43.

Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.

Emons G, Günthert A, Thiel FC, Camara O, Strauss HG, Breitbach GP, Kölbl H, Reimer T, Finas D, Rensing K; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO).

Gynecol Oncol. 2013 Jun;129(3):495-9. doi: 10.1016/j.ygyno.2013.02.039. Epub 2013 Mar 13.

PMID:
23500091
44.

Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer.

Camps J, Pitt JJ, Emons G, Hummon AB, Case CM, Grade M, Jones TL, Nguyen QT, Ghadimi BM, Beissbarth T, Difilippantonio MJ, Caplen NJ, Ried T.

Cancer Res. 2013 Mar 15;73(6):2003-13. doi: 10.1158/0008-5472.CAN-12-3159. Epub 2013 Jan 14.

45.

Transvaginal Ultrasound for Endometrial Carcinoma Screening - Current Evidence-based Data.

Steiner E, Juhasz-Bösz I, Emons G, Kölbl H, Kimmig R, Mallmann P; für die AGO Uterus der DGGG .

Geburtshilfe Frauenheilkd. 2012 Dec;72(12):1088-1091.

46.
47.

Antiproliferative effects of kisspeptin‑10 depend on artificial GPR54 (KISS1R) expression levels.

Ziegler E, Olbrich T, Emons G, Gründker C.

Oncol Rep. 2013 Feb;29(2):549-54. doi: 10.3892/or.2012.2135. Epub 2012 Nov 14.

PMID:
23152107
48.

Cell-free fetal DNA and adverse outcome in low risk pregnancies.

Stein W, Müller S, Gutensohn K, Emons G, Legler T.

Eur J Obstet Gynecol Reprod Biol. 2013 Jan;166(1):10-3. doi: 10.1016/j.ejogrb.2012.09.006. Epub 2012 Sep 27.

PMID:
23021026
49.

Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.

Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.

Int J Oncol. 2012 Nov;41(5):1845-54. doi: 10.3892/ijo.2012.1591. Epub 2012 Aug 21.

PMID:
22922893
50.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891

Supplemental Content

Support Center